College of Korean Medicine, Wonkwang University, Iksandaero 460, Iksan 54538, Jeollabuk-do, Republic of Korea.
Department of Internal Medicine and Neuroscience, College of Korean Medicine, Wonkwang University, Iksandaero 460, Iksan 54538, Jeollabuk-do, Republic of Korea.
Medicina (Kaunas). 2023 Sep 27;59(10):1730. doi: 10.3390/medicina59101730.
: Diabetes can cause various vascular complications. The Compounded Danshen-Dripping-Pill (CDDP) is widely used in China. This study aimed to analyze the effectiveness and safety of CDDP in the blood viscosity (BV) with type 2 diabetes mellitus (T2DM). : We conducted a systematic search of seven databases from their inception to July 2022 for randomized controlled trials that used CDDP to treat T2DM. To evaluate BV, we measured low shear rate (LSR), high shear rate (HSR), and plasma viscosity (PV). Homocysteine and adiponectin levels were also assessed as factors that could affect BV. : We included 18 studies and 1532 patients with T2DM. Meta-analysis revealed that CDDP significantly reduced LSR (mean difference [MD] -2.74, 95% confidence interval [CI] -3.77 to -1.72), HSR (MD -0.86, 95% CI -1.08 to -0.63), and PV (MD -0.37, 95% CI -0.54 to -0.19) compared to controls. CDDP also reduced homocysteine (MD -8.32, 95% CI -9.05 to -7.58), and increased plasma adiponectin (MD 2.72, 95% CI 2.13 to 3.32). Adverse events were reported less frequently in the treatment groups than in controls. : CDDP is effective in reducing BV on T2DM. However, due to the poor design and quality of the included studies, high-quality, well-designed studies are required in the future.
糖尿病可引起多种血管并发症。复方丹参滴丸(CDDP)在中国被广泛应用。本研究旨在分析 CDDP 对 2 型糖尿病(T2DM)患者血液黏度(BV)的有效性和安全性。
我们系统地检索了从建库到 2022 年 7 月 7 个数据库中的随机对照试验,这些试验使用 CDDP 治疗 T2DM。为了评估 BV,我们测量了低切变率(LSR)、高切变率(HSR)和血浆黏度(PV)。还评估了同型半胱氨酸和脂联素水平作为可能影响 BV 的因素。
我们纳入了 18 项研究,共 1532 例 T2DM 患者。Meta 分析显示,与对照组相比,CDDP 能显著降低 LSR(平均差 [MD] -2.74,95%置信区间 [CI] -3.77 至 -1.72)、HSR(MD -0.86,95% CI -1.08 至 -0.63)和 PV(MD -0.37,95% CI -0.54 至 -0.19)。CDDP 还能降低同型半胱氨酸(MD -8.32,95% CI -9.05 至 -7.58),增加血浆脂联素(MD 2.72,95% CI 2.13 至 3.32)。治疗组不良反应报告频率低于对照组。
CDDP 能有效降低 T2DM 患者的 BV。但是,由于纳入研究的设计和质量较差,未来需要进行高质量、精心设计的研究。